Pharmacyclics Reaches New 52-Week High (PCYC)

NEW YORK ( TheStreet) -- Pharmacyclics Incorporated (Nasdaq: PCYC) hit a new 52-week high Thursday as it is currently trading at $27.49, above its previous 52-week high of $26.73 with 365,323 shares traded as of 10:25 a.m. ET. Average volume has been 823,600 shares over the past 30 days.

Pharmacyclics has a market cap of $1.25 billion and is part of the health care sector and drugs industry. Shares are up 70% year to date as of the close of trading on Wednesday.

Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on discovering, developing, and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The company has a P/E ratio of 106, above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Pharmacyclics as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full Pharmacyclics Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Boeing Slides as China Premier Li Says Willing to Continue Talks With Airbus

Boeing Slides as China Premier Li Says Willing to Continue Talks With Airbus

Intel Gets a Downgrade Following CEO Resignation

Intel Gets a Downgrade Following CEO Resignation

Dow Falls Sharply as Wall Street Weighs Trump's New Trade Threats

Dow Falls Sharply as Wall Street Weighs Trump's New Trade Threats

Jim Cramer: Reports of Attempted Trade Truce With China Are False

Jim Cramer: Reports of Attempted Trade Truce With China Are False

Ford and General Motors 'Notably Vulnerable' to Trade War: Moody's

Ford and General Motors 'Notably Vulnerable' to Trade War: Moody's